Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm

Phase 4

Not yet recruiting

• Conditions: Benign Essential Blepharospasm; Hemifacial Spasm

• Registration Number: NCT06195241
• Lead Sponsor: Montefiore Medical Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-22
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Not yet recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Inclusion Criteria:<br><br> - Benign essential blepharospasm (BEB) or hemifacial spasm (HFS) as diagnosed by an<br> ophthalmologist.<br><br> - No known neurologic or neuromuscular systematic medications.<br><br> - No history or surgical intervention for BEB or HFS.<br><br>Exclusion Criteria:<br><br> - Patients will be excluded if age < 18, are pregnant, non-willing, or with<br> contra-indications to botulinum toxin.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Therapeutic Response based on the Jankovic Rating Scale;Therapeutic Response based on the Jankovic Rating Scale;Therapeutic Response based on the Jankovic Rating Scale

Secondary Outcome Measures

Name	Time	Method
Duration of Treatment Effect;Subjective Response to Treatment;Subjective Response to Treatment;Subjective Response to Treatment;Incidence Rate of Treatment Failure